Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $65.9 million.

  • Sutro Biopharma's Cash & Equivalents fell 6223.66% to $65.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.9 million, marking a year-over-year decrease of 6223.66%. This contributed to the annual value of $190.3 million for FY2024, which is 17473.58% up from last year.
  • As of Q3 2025, Sutro Biopharma's Cash & Equivalents stood at $65.9 million, which was down 6223.66% from $64.0 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Cash & Equivalents peaked at $235.1 million during Q2 2023, and registered a low of $28.9 million during Q1 2022.
  • In the last 5 years, Sutro Biopharma's Cash & Equivalents had a median value of $65.9 million in 2025 and averaged $85.8 million.
  • In the last 5 years, Sutro Biopharma's Cash & Equivalents plummeted by 8524.68% in 2021 and then surged by 21516.92% in 2022.
  • Over the past 5 years, Sutro Biopharma's Cash & Equivalents (Quarter) stood at $30.4 million in 2021, then skyrocketed by 55.37% to $47.3 million in 2022, then soared by 46.59% to $69.3 million in 2023, then soared by 174.74% to $190.3 million in 2024, then tumbled by 65.36% to $65.9 million in 2025.
  • Its Cash & Equivalents stands at $65.9 million for Q3 2025, versus $64.0 million for Q2 2025 and $106.2 million for Q1 2025.